BCAR3

Across TCGA pan-cancer cohorts, BCAR3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BCAR3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where BCAR3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BCAR3 is over-expressed in tumor, although a few such as LUAD and CCRCC show the opposite, repressed pattern.

LUAD, PDAC, and CCRCC are the cancer types where BCAR3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCAR3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.465	<.001	9	view →
PDAC	Female	All	+0.702	<.001	7	view →
CCRCC	Male	III,IV	−0.320	<.001	7	view →
LSCC	Male	All	−0.182	<.001	5	view →
HNSC	Female	All	+0.387	.012	3	view →
COAD	Male	All	−0.684	.030	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BCAR3–LUAD

Open the LUAD breakdown →